Lori Anne Kunkel
CIK 1536368 · Acting-Chief Medical Officer · last filed 2026-07-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.32M
Companies
7
Total Filings
50
Lifetime Open-Market Net
-$10.61M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELVN | Director | 47,773 | $53.76 | $2.57M | -$504.9K | 1 | 2026-07-08 |
| IMRA | Director | 51,884 | $14.49 | $751.8K | -$345.4K | 5 | 2026-06-09 |
| ORIC | Director | 84,200 | $11.91 | $1.00M | $0 | 11 | 2026-01-06 |
| NRIX | Director | 0 | $24.15 | $0 | $0 | 6 | 2025-05-19 |
| CRIS | Director | 56 | $4.83 | $270 | -$15.6K | 8 | 2022-01-31 |
| Forte Biosciences, Inc. (TOCA) Delisted | Acting-Chief Medical Officer | — | — | — | $0 | 4 | 2019-10-04 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 500 | — | — | -$9.75M | 10 | 2019-02-15 |
Recent Filings · Page 2 of 5
50 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-10 | IMRA | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2024-07-18 | NRIX | Gift (G) | −54,027 | $0 | EDGAR |
| 2024-06-14 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2024-06-04 | ORIC | Exer (M) | +20,500 | $76.9K | EDGAR |
| 2024-05-20 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2024-04-10 | IMRA | Grant (A) | — | $0 | EDGAR |
| 2023-06-15 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2023-05-04 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | ORIC | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.